Ads
related to: lutetium treatment for prostate cancer
Search results
Results from the WOW.Com Content Network
Lutetium (177 Lu) vipivotide tetraxetan, sold under the brand name Pluvicto, is a radiopharmaceutical medication used for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). [5] [6] Lutetium (177 Lu) vipivotide tetraxetan is a targeted radioligand therapy. [6] [8]
Pluvicto also uses Lu-177 as the radioisotope (which is a beta emitter that decays to Hf-177) but its ligand is a prostate-specific membrane antigen (PSMA) targeted ligand as this radioligand therapy addresses metastatic prostate cancer. [29] It was FDA approved in 2022.
Lutetium (177 Lu) oxodotreotide or 177 Lu dotatate, brand name Lutathera, is a chelated complex of a radioisotope of the element lutetium with dotatate, used in peptide receptor radionuclide therapy. Specifically, it is used in the treatment of cancers which express somatostatin receptors. [5] It is a radiolabeled somatostatin analog. [3] [6] [7]
177 Lu-PSMA-617 and 68 Ga-PSMA-617 are in development to treat, image, monitor and stage prostate cancer. PSMA-617 is a ligand of prostate-specific membrane antigen (PSMA) expressed on the majority of prostate tumor cells. 177 Lu-PSMA-617 also known as lutetium (177 Lu) vipivotide tetraxetan is being developed to treat prostate cancer by ...
Complete or partial treatment response has been seen in 20-30% of patients in trials treated with 177 Lu-DOTATATE or 90 Y-DOTATOC, among the most widely used PRRT drugs. [ 1 ] [ 11 ] [ 12 ] [ 13 ] When it comes to comparing these two PRRT, Y-labeled and Lu-labeled PRRTs, it appears that Y-labeled is more effective for larger tumors, while Lu ...
Researchers have discovered that a naturally-occurring molecule could potentially be an effective first line of treatment against prostate cancer. ... Prostate cancer is the most common cancer in ...
Ads
related to: lutetium treatment for prostate cancer